Multiparametric cardiovascular magnetic resonance evaluation of myocardial perfusion, oxygenation, and energetics in hypertrophic cardiomyopathy following cardiac myosin inhibitor therapy.
Finnigan LEM. et al, (2025), Eur Heart J Cardiovasc Imaging, 26
Myocardial disarray and fibrosis across hypertrophic cardiomyopathy stages associate with ECG markers of arrhythmic risk.
Ashkir Z. et al, (2025), Eur Heart J Cardiovasc Imaging, 26, 218 - 228
1H and 31P MR Spectroscopy to Assess Muscle Mitochondrial Dysfunction in Long COVID.
Finnigan LEM. et al, (2024), Radiology, 313
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study.
C-MORE/PHOSP-COVID Collaborative Group None., (2023), Lancet Respir Med, 11, 1003 - 1019
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study.
Jackson C. et al, (2023), Lancet Respir Med, 11, 673 - 684
Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls.
Zheng B. et al, (2023), Lancet Reg Health Eur, 29
Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study.
McAuley HJC. et al, (2023), EClinicalMedicine, 57
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
Liew F. et al, (2023), EBioMedicine, 87
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study.
PHOSP-COVID Collaborative Group None., (2022), Lancet Respir Med, 10, 761 - 775